
Overview
Arthec is a company that develops the Pearl method, a tissue-engineered solution for osteoarthritis that aims to regenerate cartilage and restore joint function without the need for invasive joint replacement surgery. The method utilizes proprietary technology to create structured cartilage tissue that mimics the properties of native cartilage, ensuring natural integration within the joint. Arthec's approach focuses on reducing invasiveness and promoting faster recovery for patients with early to moderate cartilage lesions.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
Financial statements were filed on time, on average 22 days early. All were audited by a statutory auditor.
- 202517/06/2026
- 202430/06/2025
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

PEARL: 12-Month Clinical Follow-Up and First Long-Term Outcome
PEARL: 12-Month Clinical Follow-Up and First Long-Term Outcome ArThec has completed the 12-month clinical follow-up of the first patient treated with its PEARL technology. This milestone provides the first long-term clinical outcome from the ongoing development of a biological approach to cartilage restoration based on autologous tissue.The development of PEARL builds on research and engineering

A Breakthrough in Joint Health
A Breakthrough in Joint Health: How the PEARL Method is Redefining Cartilage Regeneration For millions of patients worldwide, articular cartilage damage means chronic pain, loss of mobility, and eventually, the need for invasive joint replacement surgeries. Articular cartilage is one of the few tissues in the human body with very limited self-regeneration capabilities, which further

The PEARL Technology
From Damage to Restoration: How PEARL Rebuilds Healthy Cartilage Imagine not having to settle for managing pain or accepting a permanent foreign object in your body. That is the promise of ArThec’s new PEARL technology.PEARL's goal is revolutionary: to be the first technology in history to achieve permanent resolution of joint degeneration and eliminating the
Industry
Offer
- Joint regeneration devices
- Osteoarthritis treatment method
- Clinical trials
- Medical solutions
Websites
- arthec.euArThec – PearlWordPress 4.2ElementorGoogle AnalyticsGoogle Tag ManagerNginx
Authorized Representatives
Manner of representation
In the case of a one-person management board, the sole member of the management board is authorised to submit declarations of will concerning the rights and obligations on behalf of the company. In the case of the appointment of a multi-member management board, joint action by two members of the management board acting jointly is required to submit declarations of will concerning the rights and obligations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Sanctions and PEP
Sanctions
No matches (EU, UN, US, UK, MSWiA, World Bank)
PEP
No matches
Bank accounts
Registered as a VAT taxpayer on 2019-09-04.
03 1050 1764 1000 0090 8068 1191
37 1050 1764 1000 0090 8629 4551
32 1050 1764 1000 0090 8629 4544
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 25, 2025 | Bankruptcy notice | |
| Apr 25, 2025 | Call to heirs |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 6, 2026 | Aid for research and development projects: experimental development | $3.5M$3,479,738 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| May 6, 2026 | Aid for research and development projects: industrial research | $1.5M$1,459,446 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Feb 19, 2020 | Aid for SME access to finance — aid for start-ups | $219.1K$219,148 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-09-08 | PEARL method – in vitro production of fully functional autologous hyaline cartilage ready for implementation, which biologically restores joint function | $4.6M$4,591,879 | European Funds for a Modern Economy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Fly-Gen sp. z o.o. | $45,325.87 | fly-gen.pl | ||
| Orphinic Scientific S.A. | $42,972.42 | orphinic.com | ||
| Biolabic sp. z o.o. | $37,688.85 | biolabic.pl | ||
| DR Joanna Sanford sp. k. | $28,674.82 | sanfordbiotech.com | ||
| Air Abrasion System sp. z o.o. | $25,764.88 | airabrasion.pl | ||
| Bonereg sp. z o.o. | $25,113.01 | bonereg.com | ||
| Thesybin Labs P.S.A. | $8,297.34 | thesybin.pl | ||
| Bioinfo Capital sp. z o.o. | $7,450.04 | bioinfo.pl | ||
| Jotachem sp. z o.o. | $6,512.58 | jotachem.pl | ||
| Poltiss sp. z o.o. | $3,843.72 | poltiss.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-04-01 | Share capital increase (100,000.00 PLN → 110,616.70 PLN) | |
| 2024-04-30 | Entered in the register |
FAQ
Last updated: 2026-06-22